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Simple Objective Detection of Human Lyme Disease Infection Using
Immuno-PCR and a Single Recombinant Hybrid Antigen
Micah D. Halpern,a Claudia R. Molins,b Martin Schriefer,b Mollie W. Jewetta
Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, Florida, USAa; Diagnostic and Reference Laboratory, Bacterial Diseases
Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USAb
A serology-based tiered approach has, to date, provided the most effective means of laboratory confirmation of clinically sus-
pected cases of Lyme disease, but it lacks sensitivity in the early stages of disease and is often dependent on subjectively scored
immunoblots. We recently demonstrated the use of immuno-PCR (iPCR) for detecting Borrelia burgdorferi antibodies in pa-
tient serum samples that were positive for Lyme disease. To better understand the performance of the Lyme disease iPCR assay,
the repeatability and variability of the background of the assay across samples from a healthy population (n 36) were analyzed.
Both of these parameters were found to have coefficients of variation of<3%. Using eight antigen-specific iPCR assays and posi-
tive call thresholds established for each assay, iPCR IgM and/or IgG diagnosis from Lyme disease patient serum samples (n 12)
demonstrated a strong correlation with that of 2-tier testing. Furthermore, a simplified iPCR approach using a single hybrid
antigen and detecting only IgG antibodies confirmed the 2-tier diagnosis in the Lyme disease patient serum samples (n 12).
Validation of the hybrid antigen IgG iPCR assay using a blinded panel of Lyme disease and non-Lyme disease patient serum sam-
ples (n 92) resulted in a sensitivity of 69% (95% confidence interval [CI], 50% to 84%), compared to that of the 2-tier analysis
at 59% (95%CI, 41% to 76%), and a specificity of 98% (95%CI, 91% to 100%) compared to that of the 2-tier analysis at 97%
(95%CI, 88% to 100%). A single-tier hybrid antigen iPCR assay has the potential to be an improvedmethod for detecting host-
generated antibodies against B. burgdorferi.
Lyme disease is the most commonly reported tick-borne illnessin the United States, with approximately 30,000 cases reported
to the Centers for Disease Control and Prevention (CDC) each
year (1). New preliminary estimates released by the CDC indicate
that the number of Americans diagnosed with Lyme disease each
year is closer to 300,000, which is roughly 10 times higher than the
annual reported number (2). This new estimate supports studies
published in the 1990s, which suggested that the number of cases
may be between 3- and 12-fold higher than the number of re-
ported cases (3, 4), making Lyme disease a significant health con-
cern in the United States. Accurate diagnosis provides a consider-
able obstacle for the clinical management of the disease and is
necessary in order to differentiate Lyme disease from other dis-
eases with similar clinical presentation. Misdiagnosis is common
due to difficulties in detecting Borrelia burgdorferi, the causative
agent of Lyme disease (5). Although a wide range of laboratory
diagnostic approaches have been explored, the currently accepted
method utilizes the detection of serological responses to B. burg-
dorferi antigens (6).
The currently acceptedmethod for diagnosing Lyme disease in
a clinical setting entails a two-tiered approach using a first-tier
enzyme-linked immunosorbent assay (ELISA), followed by a sec-
ond-tier immunoblot assay for both IgM and IgG B. burgdorferi-
specific antibodies using whole-cell B. burgdorferi lysates, recom-
binant antigens, or various combinations, depending on the
commercial kit used (7). The ELISA provides an objective and
sensitive first-tier screen but lacks the specificity and broad strain
applicability (8) required for a standalone test. The second-tier
immunoblot provides a higher level of specificity but currently
requires somewhat subjective analysis due to its qualitative nature
and general lack of automation (9). A tiered approach has to date
provided themost effectivemeans of diagnosing Lyme disease in a
clinical setting (7).
Other approaches for diagnosing Lyme disease have been de-
veloped, including live culture, PCR, and additional molecular-
based approaches, with no method surpassing the effectiveness of
a serology-based approach. The detection of typical erythema
migrans (EM) can be sufficient for a clinical diagnosis of early
localized Lyme disease in the absence of laboratory tests (7). How-
ever, this manifestation is not present in all patients (7), further
highlighting the need for improved methods for early objective
diagnosis of Lyme disease. In our previous study, we demon-
strated the use of immuno-PCR (iPCR) for detecting host-gener-
ated antibodies in a murine model, and we presented preliminary
data using serum samples collected from Lyme disease patients
and healthy controls (10).Our results indicated that iPCRusingB.
burgdorferi whole-cell sonicates and a limited number of B. burg-
dorferi recombinant antigens provided higher sensitivity for de-
tecting B. burgdorferi antibodies in infected mice and an equiva-
lent sensitivity for detecting B. burgdorferi antibodies in Lyme
disease patient serum compared to both ELISA and the immuno-
blot (10).
It is well established that multiple antigens are required for an
accurate overall diagnosis of themultiple stages and types of Lyme
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disease (7). Furthermore, it is critical that the antigens used for
diagnosis are demonstrated to have low cross-reactivity for dis-
eases other than Lyme disease. The goals of this study were to (i)
determine the range of the levels of background detection of the
Lyme disease iPCR assays across a healthy human population, (ii)
explore a larger subset of antigens for assay sensitivity and speci-
ficity, and (iii) compare the performance of the optimized Lyme
disease iPCR protocol with that of the current 2-tier method of
Lyme disease diagnosis.
MATERIALS AND METHODS
Healthy human sera. The current study was approved by the University
of Central Florida’s institutional review board (UCF IRB) (FWA00000351
and IRB00001138). All procedures and investigators involved in the sam-
ple collection process were approved by the UCF IRB with Collaborative
Institutional Training Initiative (CITI) training. All donors provided
written consent to participate in the study. Sample collection was under-
taken at the University of Central Florida campus. UCF is a diverse com-
munity of nearly 60,000 students and approximately 8,000 faculty and
staff members of various ages and ethnic and racial backgrounds. Individ-
uals were included in the study if they had not been previously diagnosed
with and/or treated for Lyme disease, received a Lyme disease vaccination,
or lived within the past 10 years in a state with a high incidence of Lyme
disease (Connecticut, Delaware, Maine, Maryland, Massachusetts, Min-
nesota, New Hampshire, New Jersey, New York, Pennsylvania, Vermont,
Virginia, and Wisconsin). Approximately 10 ml of blood was sampled,
according to the IRB-approved protocol, from 36 individuals into serum
separator tubes, inverted five times to mix the clot activator with the
blood, and allowed to clot for30min. Serum fractions were collected by
centrifugation at 1,200 g for 10 min. The serumwas further clarified by
centrifugation at 9,100 g for 5min to remove any insolublematerial and
stored at 4°C for short-term or80°C for long-term storage.
Lyme disease human serum panel. The CDC research panel I con-
sisted of patient serum samples collected from 32 individuals, including
patients with stage 1, 2, or 3 Lyme disease (n  12), look-alike diseases,
including fibromyalgia, rheumatoid arthritis, multiple sclerosis, mono-
nucleosis, syphilis, and severe periodontitis (n  12), as well as healthy
individuals from areas of endemicity (n 4) and nonendemicity (n 4)
for Lyme disease. All Lyme disease patients were diagnosed by a physician,
stage 1 and 2 patients were confirmed by culture and/or PCR detection of
B. burgdorferi, and stage 3 patients were positive by two-tiered testing. The
CDC-recommended two-tiered testing algorithm (6) was performed us-
ing FDA-cleared assays for Lyme disease and consisted of a first-tier
whole-cell sonicate enzyme immunoassay (VIDAS Lyme IgM and IgG
polyvalent assay; bioMérieux, Inc.,Durham,NC), followedby second-tier
IgM and IgG immunoblots (IB) (MarDxDiagnostics, Inc., Carlsbad, CA).
The blinded CDC research panel II consisted of serum samples collected
from 92 individuals, including patients with stage 1, 2, or 3 Lyme disease
(n 32), look-alike diseases, including fibromyalgia, rheumatoid arthri-
tis, multiple sclerosis, mononucleosis, syphilis, and severe periodontitis
(n 36), as well as healthy individuals from areas of endemicity (n 12)
and nonendemicity (n 12) for Lyme disease. The laboratory support of
Lyme disease diagnosis was the same as for CDC research panel I. Prior to
analysis, all serum sampleswere clarified by centrifugation at 9,100 g for
5 min to remove any insoluble material and put in the short-term storage
at 4°C.
Cloning and expression of recombinant antigens lacking GST fu-
sion tags. Recombinant glutathione S-transferase (rGST)-BmpA and
rGST-OspC were constructed as previously described (10). In-frame glu-
tathione S-transferase (GST) fusion proteins for BBK19, OspA, DbpA,
RevA, Crasp-2, and BBK50 were generated by PCR amplification of the
corresponding coding regions, without the signal sequences fromB. burg-
dorferi genomic DNA, using primer pairs 1147 and 1148 (BBK19), 1151
and 1152 (OspA), 1145 and 1146 (DbpA), 1143 and 1144 (RevA),
1149 and 1150 (Crasp-2), or 1043 and 1044 (BBK50) engineered with
BamHI and SalI or XhoI restriction sites (Table 1) and Phusion polymer-
ase (New England BioLabs, Ipswich, MA). The PCR products were puri-
fied (Qiagen, Valencia, CA), digested with the appropriate restriction en-
zymes (New England BioLabs), and cloned into BamHI- and SalI- or
TABLE 1 iPCR DNA oligonucleotide sequences used in this study
Oligo no. Oligo IDa Sequence (5= to 3=)b
T1 Template 1 (IgG coupled) Biotin-agcctcagaccaagccagacaactgcctcgtgacgttgctgcccctaccaacgtacccctacgagtcc
T1F Template 1 forward agcctcagaccaagccagac
T1R Template 1 reverse ggactcgtaggggtacgttgg
T1P Template 1 probe FAM-actgcctcgtgacgttgctgcccct-BHQ1
T2 Template 2 (IgM coupled) Biotin-aggaggagggtcaagtcaccaacgctgctccaggccatcgtgctgatctggaccctggatcgagtga
T2F Template 2 forward aggaggagggtcaagtcacc
T2R Template 2 reverse tcactcgatccagggtccag
T2P Template 2 probe MAX-acgctgctccaggccatcgtgctga-BHQ1
1147 BBK19 F CGGGATCCttttcaaaagattctcgatcacg
1148 BBK19 R ACGCCTCGAGtcaattgttaggtttttcttttcc
1151 OspA F CGGGATCCaagcaaaatgttagcagcc
1152 OspA R ACGCCTCGAGttattttaaagcgtttttaatttcatcaag
1145 DbpA F CGGGATCCggactaacaggagcaacaa
1146 DbpA R ACGCCTCGAGttagttatttttgcatttttcatcag
1143 RevA F CGGGATCCaaagcatatgtagaagaaaagaaag
1144 RevA R ACGCCTCGAGttaattagtgccctcttcg
1149 Crasp2 F CGGGATCCgatgttagtagattaaatcagagaaatatt
1150 Crasp2 R ACGCCTCGAGctataataaagtttgcttaatagctttataag
1043 BBK50 F CGGGATCCatgtgtaaattatatgaaaagcttacaaataaatcgc
1044 BBK50R CCGCTCGAGttatctagagtccatatcttgcaattt
1084 DbpA_PEPC10 R AGGTTTTTTTGGACTTTCTGCCACAACAGGgttatttttgcatttttcatcagtaaaagt
1085 C6_PEPC10 F CCTGTTGTGGCAGAAAGTCCAAAAAAACCTatgaagaaggatgatcagattgc
1023 C6 Bb R ACGCGTCGACttacttcacagcaaactttccatc
a ID, identification.
b Uppercase letters indicate nontemplate sequence used for the addition of terminal restriction sites, epitope tags, or synthetic assembly. FAM, 6-carboxyfluorescein; BHQ1, black
hole quencher 1.
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XhoI-digested pGEX-6P-1 (GE Healthcare, Piscataway, NJ) to generate
translational fusions with GST at the N terminus. Subsequent clones were
selected and the sequence confirmed by sequence analysis. pGEX-6P-1
plasmids carrying the bmpA, ospC, bbk19, ospA, dbpA, revA, crasp-2, and
bbk50 genes were transformed into Escherichia coli strain BL21 (Novagen,
Billerica,MA). Protein expressionwas induced by the growth of BL21 cells
containing the expression construct for each B. burgdorferi antigen in 50
to 100 ml of MagicMedia E. coli expression medium, according to the
manufacturer’s protocol (Invitrogen, Carlsbad, CA) for 24 h at 37°C with
aeration. Recombinant protein purification was performed according to
the procedures outlined in the BulkGSTpurificationmodule (GEHealth-
care). The purified proteins were dialyzed in Tris-buffered saline (50 mM
Tris-HCl, 150mMNaCl [pH 7.5]) overnight at 4°C using D-Tube dialyz-
ers (EMD Millipore Chemicals, Philadelphia, PA) and two buffer ex-
changes to remove excess glutathione. The dialyzed proteins were sub-
jected to protease cleavage of the GST tag overnight at 4°C, according to
procedures outlined in the PreScission protease kit (GE Healthcare).
Cleaved proteins were purified from GST and excess protease using two
rounds of Bulk GST purification (GE Healthcare) and collection of the
eluent. Purified proteins lacking a GST tag were concentrated using Ami-
con Ultra-2 centrifugal filter devices (EMD Millipore Chemicals) to a
volume of approximately 80 l and stored at 4°C. The total protein con-
tent was quantified by absorbance spectrophotometry at a wavelength of
280 nm. Recombinant protein purity and seroreactivity were determined
by Coomassie gel staining and immunoblot using infected mouse serum.
Briefly, 100 ng of each recombinant protein was separated by 12.5% poly-
acrylamide gel electrophoresis. For Coomassie staining, the gels were in-
cubated in Imperial protein stain (Thermo Scientific, Rockford, IL) for 1
h and destained in deionized water for 1 h prior to imaging. For immu-
noblot analysis, the proteins were transferred to a nitrocellulose mem-
brane, and themembrane was blocked in 5% skimmilk and incubated for
1 h with mouse serum samples collected 3 weeks postinoculation with
wild-type B. burgdorferi, as previously described (10), diluted 1:200 in
Tris-buffered saline–0.05% Tween (TBST) (pH 7.6), washed twice with
TBST, incubated with horseradish peroxidase (HRP)-conjugated goat
anti-mouse IgG/IgM (Chemicon International, Billerica, MA) for 1 h,
washed twice with TBST, and the signal was detected using the SuperSig-
nal West Pico chemiluminescent substrate kit (Thermo Scientific).
Cloning and expression of the recombinant DOC antigen. An in-
frame glutathione S-transferase (GST) fusion protein for the DOC hybrid
protein was generated using two distinct PCR amplification steps. First,
the corresponding coding regions for DbpA and the C6 peptide of VlsE
(11) were amplified separately from B. burgdorferi strain B31 genomic
DNA, and the PEPC10 sequence (12) was added to each amplicon using
the primer pairs 1145 and 1084 (DbpA-PEPC10) and 1085 and 1023 (C6-
PEPC10), respectively, engineered with BamHI/SalI restriction sites (Ta-
ble 1). Both PCR products were diluted 100-fold, combined, and synthet-
ically assembled into the DOC construct by overlapping PCR using the
primer pairs 1145 and 1023. The final constructs were sequenced and
verified, and the recombinant protein was generated and purified as de-
scribed above for the other B. burgdorferi antigens.
iPCR reagents, assay, and signal amplification. iPCR reagents were
prepared and the assays conducted as previously described (10), with
minor modifications. Briefly, iPCR assays were assembled in a two-sided
(sandwich) manner, as detailed in Fig. 1A, with the capability to simulta-
neously capture and report both IgM and IgG host-generated antibodies
(Fig. 1B). Recombinant antigens lacking fusion tags were used to coat
magnetic beads for host antibody capture using 10 to 20g of antigen per
mg of beads. The beads were resuspended in 500 l TBST for secondary
antibody incubation. Signal amplification by real-time quantitative PCR
was accomplished as previously described (10), and the quantification
cycle (Cq) for each reaction was determined using a manual baseline de-
termination (cycle 10 to 20) and a manual threshold setting of 1.0.
The PCR plate set-ups for all experiments included, in duplicate, a
PCR-negative template control consisting of water and an iPCR bead
processing negative control that contained the TBST stock used for pro-
cessing to determine the sample-to-sample contamination. Additionally,
each PCR run included calibrator plasmids carrying the cloned template
for the IgMor IgG reporter oligonucleotides that were used to account for
run-to-run variation in the threshold calculation between the PCR plates.
Briefly, the baseline was manually adjusted such that the Cq values for the
calibrator plasmids were set at a constant value for each plate to account
for minor variability in the threshold setting.
Positive threshold value and data analysis. The results of the Lyme
disease iPCR assay were reported asCq values. TheCq value was calcu-
lated as the difference between the antigen-/isotype-specific background
threshold Cq value and the Cq value of the sample. The antigen-/isotype-
specific background threshold Cq values were calculated as the mean Cq
value of each antigen-isotype combination for a group of 16 healthy indi-
viduals minus a specific multiple of the standard deviation (SD) of the
mean. The antigen-specific multiplier was set at a minimal value (1.9 to
6.6 for IgMand 3.1 to 5 for IgG), such that the samples fromall individuals
without Lyme disease in CDC research panel I resulted in a Lyme disease
iPCR Cq value of 0. Using these antigen-/isotype-specific thresholds,
any sample that resulted in a Lyme disease iPCR Cq of 0 was called
iPCR positive. The coefficient of variation (CV)was calculated as the ratio
of the SD to the mean. Assay sensitivity and specificity and the associated
95% confidence intervals were calculated using GraphPad Prism 5.0 for
Windows (GraphPad Software).
RESULTS
Lyme disease iPCR demonstrates strong within-assay precision
and reproducible background across a sample population of
healthy individuals.We previously demonstrated proof-of-prin-
ciple for iPCR detection of human host-generated B. burgdorferi
antibodies using VlsE C6 peptide-coated magnetic beads and a
panel of serum samples (n 36) from Lyme disease-positive and
FIG 1 Schematic representation of the multiplex iPCR assay for detection of
Lyme disease host antibodies using recombinant antigens. (A) A recombinant
B. burgdorferi protein antigen coupled to magnetic beads was used to capture
B. burgdorferi-specific host-generated antibodies. A biotinylated DNA oligo-
nucleotide reporter molecule coupled to a streptavidin-conjugated reporter
antibody was amplified by qPCR for detection and quantification. (B) The
same antigen-coupled beadswere used to simultaneously capture IgMand IgG
host-generated antibodies, which were detected in a multiplex fashion using
isotype-specific secondary antibodies coupled to unique reporter oligonucle-
otides (T1 and T2) similarly amplified by qPCR for detection and quantifica-
tion.
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Lyme disease-negative patients and healthy controls (10). This
feasibility study was accomplished using a small number of sam-
ples from healthy controls (n 5) to determine test efficiency and
background threshold levels. In an effort to establish a better un-
derstanding of the performance of the Lyme disease iPCR assay,
including the repeatability and the variability of the backgroundof
the assay across a healthy population, the number of replicates and
overall sample size of healthy individualswere expanded. Prospec-
tive blood samples were collected from consenting individuals
without a history of Lyme disease under the approval of the Uni-
versity of Central Florida’s institutional review board. To assess
assay repeatability, a serum sample from a single healthy individ-
ual was tested 18 times using the same reagent preparation lots,
including DbpA antigen-coated beads and oligonucleotide-la-
beled secondary antibodies. The DbpA protein was selected as a
representative in vivo-expressedB. burgdorferi antigen. The results
of this analysis demonstrated lowwithin-assay variability for both
the IgM- and IgG-specific detection reagents, as indicated by stan-
dard deviation values for each data set of 0.39 and 0.73, respec-
tively, and coefficient of variation values for each data set of 1.34%
and 2.30%, respectively (Fig. 2).
To determine the variability in the background of the Lyme
disease iPCR assay across a healthy human population, the serum
samples from 36 healthy individuals were tested in duplicate using
magnetic beads coated with the DbpA antigen and the oligonucle-
otide-labeled IgM and IgG secondary antibodies used for the re-
peatability analysis. Similar to the within-sample repeatability
analysis, the results of the between-sample variability analysis
demonstrated a standard deviation across the population of 0.79
for the background detection of IgM antibodies and 0.84 for IgG
antibodies; the coefficients of variation were 2.66% and 2.63%,
respectively (Fig. 3).
Mean and standard deviation background values across a
population of healthy individuals are unique for each Lyme dis-
ease iPCR assay antigen-isotype combination. The analysis of
the Lymedisease iPCRassay repeatability andpopulation variabil-
ity using DbpA-coupled magnetic beads demonstrated that the
mean background value for the detection of IgM versus IgG anti-
bodies differed by as much as2.5 Cq values (Fig. 2 and 3). Based
on this observation, we predicted that depending on the different
antigen used, each Lyme disease iPCR assay would result in a
distinct mean background Cq value. If true, this finding would
FIG 2 Lyme disease immuno-PCR magnetic bead protocol demonstrates
strong within-assay precision. (A) Serum collected from a single healthy indi-
vidual was assayed 18 times by IgM/IgG multiplex iPCR using recombinant
DbpA antigen coupled to magnetic beads. Each dot represents a single repli-
cate, and the horizontal line represents the mean Cq value for all replicates for
each isotype. The y axis represents the quantification cycle (Cq) determined by
real-time quantitative PCR. (B) The mean, standard deviation (SD), range,
and coefficient of variation (CV) (calculated as the ratio of the SD to themean)
were calculated for both the IgM and IgG Cq values.
FIG 3 Lyme disease immuno-PCR demonstrates reproducible background
across a healthy human population for both IgM and IgG isotypes using the
DbpA antigen. Serum samples from 36 healthy individuals were assayed in
duplicate by multiplex iPCR using both IgM (A) and IgG (B) secondary anti-
bodies and recombinant DbpA antigen-coupled magnetic beads. Each dot
represents a single replicate per individual, with the horizontal lines represent-
ing the mean value for duplicate serum samples from each individual. The y
axis represents the quantification cycle (Cq) determined by real-time quanti-
tative PCR. (C) The mean, standard deviation (SD), range, and coefficient of
variation (CV) (calculated as the ratio of the SD to the mean) is listed for each
isotype.
Hybrid Antigen iPCR Detection of Lyme Disease
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impact the determination of the background threshold setting for
the assay, making it necessary to assign a distinct background
threshold for each antigen-isotype combination. To test this hy-
pothesis, we compiled a list from the literature of B. burgdorferi
proteins that are known or hypothesized to be seroreactive in hu-
mans (13–27). From this list, a subset of 8 B. burgdorferi antigens
was selected for further analysis in our assay due to their ability to
be produced in large quantities as recombinant in-frame N-ter-
minal glutathione S-transferase (GST) fusion proteins in E. coli.
To eliminate any possibility of antibody cross-reactivity to the
GST tag, this sequence was proteolytically removed. The purity
and antigenicity of each recombinant antigen were demonstrated
by SDS-PAGE, followed by Coomassie brilliant blue staining and
immunoblot analysis using pooled sera collected from B. burgdor-
feri-infected mice (see Fig. S1 in the supplemental material).
Each antigen was coupled to magnetic beads and examined by
Lyme disease iPCR for both IgM and IgG background reactivities
across 16 serum samples collected from healthy individuals. As
predicted, all antigen-isotype combinations demonstrated unique
background values that ranged from a mean Cq of 26.09 to 32.46
for IgMand 25.30 to 36.62 for IgG and a standard deviation of 0.40
to 1.53 for IgM and 0.37 to 1.47 for IgG (Fig. 4).
Multiplex iPCR detection of IgM and/or IgG host response
antibodies against B. burgdorferi using a panel of antigens has
the potential for improved sensitivity compared to 2-tier test-
ing. Most existing protocols for Lyme disease diagnostics require
the use of multiple antigens to diagnose the disease. In an effort to
further explore the application of iPCR as a Lyme disease diagnostic,
we sought to develop a similar methodology that utilizes a com-
bination of results for different antigens to facilitate diagnosis. The
panel of eight B. burgdorferi antigens was tested against the CDC
research panel I collection of sera using multiplex iPCR for the
simultaneous detection of IgM and IgG host-generated anti-
bodies. The same human serum panel was previously tested
according to CDC guidelines by a commercial enzyme-linked
immunosorbent assay (ELISA), followed by IgM and IgG immu-
noblot (IB), and classified for 2-tier testing status (see Table S1 in
the supplemental material). Samples were considered positive by
iPCR if they resulted in aCq value that was0 for IgMor IgG for
one or more of the eight antigens tested. The Cq value was cal-
culated as the difference between the antigen-/isotype-specific
background threshold Cq value and the Cq value of the sample.
The antigen-/isotype-specific background threshold Cq values
were calculated as themeanCq value of each antigen-isotype com-
bination for a group of 16 healthy individuals minus a specific
multiple of the standard deviation (SD) of themean (Fig. 4). Each
antigen-specific multiplier was set at a minimum value (1.3 to 6.6
for IgM and 2.8 to 5 for IgG; see Table S2 in the supplemental
material), such that the samples from all individuals without
Lyme disease in CDC research panel I resulted in a Lyme disease
iPCRCq value of0. Using these criteria, iPCR testing provided
similar results to those of 2-tier testing for the Lyme disease pa-
tient samples, with one exception (see Table S1 in the supplemen-
tal material). A single early Lyme disease patient sample that was
deemed negative by 2-tier testing was positive by iPCR (see Table
S1, sample A4). It should also be noted that no single antigen
provided iPCR-positive results across all Lyme disease patient
samples, which comprised different stages and clinical presenta-
tions of disease.
Simplified single hybrid antigen iPCRdetection of host-gen-
erated IgGantibodies alone confirms 2-tier results for a panel of
human serum samples. iPCR testing with the panel of eight B.
burgdorferi antigens showed strong potential as a Lyme disease
diagnostic method by reproducing the 2-tier test results for CDC
research panel I Lyme disease patient samples. Although success-
ful, the use of multiple antigens tested against IgM and IgG in-
creases test complexity by requiring the testing of a single sample
with multiple antigens. In an effort to further simplify the Lyme
disease iPCR approach, we theorized that a single hybrid antigen
composed of the immunogenic epitopes ofmultiple B. burgdorferi
antigens would provide results similar to those of testing with a
panel of whole individual antigens. To examine the applicability
FIG 4 Immuno-PCR demonstrates low intra-antigen background variability
for an antigen panel across a healthy human population. Serum samples from
16 healthy individuals were assayed by multiplex iPCR for both IgM (A) and
IgG (B) host-generated antibodies against recombinant DbpA, BmpA, OspC,
BBK19, OspA, RevA, Crasp2, and BBK50 antigen-coupled magnetic beads.
Each point represents a single individual replicate, and the horizontal lines
represent the mean Cq values for all individuals for each antigen/isotype com-
bination. Each antigenmean and standard deviation (SD) value is listed. The y
axis represents the quantification cycle (Cq) determined by real-time PCR. The
across-population mean, standard deviation, range, and coefficient of varia-
tion (CV) values are shown for each antigen/isotype combination.
Halpern et al.
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of a single hybrid antigen for iPCR detection of host-generated
antibodies against B. burgdorferi infection, we synthetically con-
structed a novel hybrid antigen composed of full-length DbpA,
the PEPC10 peptide (OspC) (12), and the C6 peptide (VlsE) (11),
referred to as the DOC antigen (Fig. 5A). Similar to the previous
eight recombinant antigens, we determined the protein purity and
seroreactivity toward B. burgdorferi-infected mouse sera of the
hybrid protein (see Fig. S1 in the supplemental material). The
range of the background reactivity of theDOCantigen in the iPCR
assay was determined using the serum from a group of 16 healthy
individuals (Fig. 5B). The results of the between-sample variabil-
ity analysis demonstrated a standard deviation across the popula-
tion of 0.57 for the background detection of IgM antibodies and
0.51 for the background detection of IgG antibodies; the coeffi-
cients of variation were 2.31% and 1.94%, respectively. Using
iPCR, we then tested the hybrid antigen in duplicate against the
CDC research panel I for IgM and IgG reactivity, utilizing the
results to establish the positive call threshold as described above.
The DOC antigen IgG results confirmed all 2-tier-positive results
(Fig. 6A). Interestingly, the Lyme disease iPCR assay using the
DOC antigen tested negative for the detection of host-generated
IgM antibodies for all human samples analyzed (Fig. 6B).
Although early, specific diagnosis is the primary goal for any
Lyme disease diagnostic, determining the stage of disease progres-
sion would provide additional information to aide in the treat-
ment of the disease. It is logical to assume that the amount of
host-generated B. burgdorferi antibody will increase with further
disease progression. Due to the quantifiable nature of iPCR test-
FIG 5 Development of a hybrid antigen for simple detection of Lyme disease.
The DOC antigen was assembled using full-length DbpA protein fused to the
PEPC10 (OspC) and the C6 (VlsE) peptides (A) and was tested by iPCR using
DOC-coated magnetic beads against 16 healthy individuals for IgM and IgG
for the range of the background reactivity (B). (B) Each dot represents a single
individual replicate, and the horizontal lines represent the mean Cq values for
all individuals for IgMand IgG. Themean, standard deviation (SD), range, and
CV values are also listed. The y axis represents the quantification cycle (Cq)
determined by real-time quantitative PCR.
FIG 6 The iPCR assay using the DOC hybrid antigen provides robust detec-
tion of Lyme disease. A serum panel composed of 32 samples and consisting of
Lyme-infected individuals both early (acute and convalescent) and late (neu-
rologic and arthritis) stage, as well as look-alike diseases and healthy individ-
uals from areas of endemicity and nonendemicity were tested in duplicate
using DOC iPCR for both IgG (A) and IgM (B) reactivity. Each dot represents
a single individual replicate, and the black horizontal lines represent the mean
Cq values for all individuals within each category. The filled circles represent
samples that were positive with 2-tier testing, and the open circles signify a
2-tier-negative status. A positive threshold value was established using a mul-
tiplier of the standard deviation (SD) above the mean value with the Cq
threshold (gray horizontal line) representing a value of zero. S1, stage 1; S2,
stage 2; S3, stage 3.
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ing, we hypothesized that the amount of anti-DOC host-gener-
ated IgG antibody correlates with disease stage. The mean 	 SD
iPCR value was1.61	 0.36 for stage 1 acute early Lyme disease
patients, 0.67 	 0.38 for stage 1 convalescent early Lyme disease
patients, and 2.39	 0.64 for stage 2/stage 3 Lyme disease patients,
for a total of n  4 samples per group. These data may suggest a
correlation of increasing antibody capture with disease progres-
sion; however, further evaluation with an increased number of
clinically defined samples is required to support this finding. It
should also be noted that the number of EM rashes documented
for each patient showed no correlation with the iPCR value for B.
burgdorferi antibody detection (data not shown).
DOC hybrid antigen iPCR demonstrates robust sensitivity
and specificity for ablindedpanel of human serumsamples.The
initial success of DOC IgG iPCR with replicating 2-tier results for
a panel of 32 human serum samples provided strong evidence for
the application of our approach as a simplified Lyme disease diag-
nostic. We next sought to perform a larger-scale blinded valida-
tion analysis of our assay. TheCDC research panel II, composed of
92 samples, including sera collected frompatients with early Lyme
disease and EM (stage 1), early Lyme disease with neurological or
cardiac evidence of dissemination (stage 2), and patients with
Lyme arthritis (stage 3), as well as look-alike diseases and healthy
donors, was tested by iPCR for host-generated IgG antibodies to
the DOC hybrid antigen, and the results were compared to those
of the 2-tier test (Table 2). Using the background threshold Cq
value for DOC/IgG established above, overall, iPCR provided lev-
els of sensitivity and specificity comparable to those of 2-tier test-
ing (Fig. 7). iPCR replicated all 2-tier-positive results. Moreover,
iPCR provided detection of an additional three early Lyme disease
samples deemed negative by 2-tier testing, leading to an overall
sensitivity for iPCR of 69% (95% confidence interval [CI], 50% to
84%) compared to the sensitivity of 2-tier testing of 59% (95%CI,
41% to 76%). The difference in sensitivity was entirely for detect-
ing stage 1 early Lyme disease samples, with sensitivity for iPCR of
55% (95%CI, 32% to 77%) and of 40% for 2-tier testing (95%CI,
19% to 64%) for this category of samples. iPCR and 2-tier testing
showed equivalent sensitivity for stage 2/stage 3 Lyme disease
samples of 92% (95% CI, 62% to 100%). iPCR detected only a
single false positive for a sample from a healthy control from an
area of endemicity (healthy endemic sample), resulting in a spec-
ificity of 98% (95% CI, 91% to 100%) compared to 2-tier testing,
which detected two false positives for look-alike diseases, provid-
ing a specificity of 97% (95% CI, 88% to 100%). For comparison,
the sensitivity and specificity for the ELISA first-tier portion of the
2-tier test were calculated to be 75% (95% CI, 57% to 89%) and
77% (95% CI, 64% to 87%), respectively.
DISCUSSION
There is an urgent need to develop new tools for improved diag-
nosis of Lyme disease. This study describes an objective Lyme
disease diagnostic method using iPCR detection of host IgG anti-
body binding to a single recombinant hybrid antigen.
Repeatability is a key parameter of any newly developed diag-
nostic test that provides confidence the test will identify individ-
uals as disease positive or negative in a reproducible manner
across the inherent variability of a human population. iPCR has
been shown to be a reproducible approach for detecting other
targets (28, 29), although this method generates a background
signal in the absence of the analyte being detected (30). The back-
ground signal has been attributed to nonspecific binding of the
oligonucleotide-labeled secondary antibody, similar to the results
observed for other immunodiagnostics (31). Although a number
of approaches have been proposed to minimize the level of back-
ground amplification (32–34), no approach to date has proven
successful at completely eliminating the background signal. For
diagnosing Lyme disease, we propose that the iPCR background
signal provides an intrinsic advantage due to the fact that a posi-
tive result is a relative measure above the established background
threshold, thereby limiting the potential contribution of contam-
ination, whereas a positive result for standard PCR is an absolute
measure that can be highly sensitive to low-level laboratory con-
tamination (7). The baseline level of amplification using iPCR for
a negative sample far surpasses any low-level laboratory contam-
ination that commonly results in false-positive detection for PCR-
based clinical diagnostic tests. As a result, the level of PCR con-
tamination required to produce a false positive above background
for iPCR is orders of magnitude above that for standard PCR. In
addition, critical to the success of this approach is a constant back-
ground that remains consistent between sample replicates and is
standardized across a healthy human population.
In an effort to determine the consistency of the background
amplification for the technique, we tested the serum from a single
healthy individual over 18 replicates using iPCR and found the
standard deviations of the mean Cq values to be 0.39 and 0.73 for
IgMand IgG, respectively, with corresponding coefficients of vari-
ation of 1.34% and 2.30%, respectively. The accepted value for
PCR sampling error is1 Cq (35), and the coefficient of variation
for an ELISA-based test is considered good at 15% (36). These
data indicate that our iPCRprotocol can provide highly consistent
and repeatable results acrossmultiple replicates of a single sample.
We proceeded to test serum samples collected from 36 healthy
individuals in duplicate for IgM and IgG reactivity using the same
antigen to determine the variability of the background across a
healthy population. As expected, compared to the within-sample
repeatability analysis, we observed a slightly higher standard devi-
ation of the mean Cq values of 0.79 and 0.84 for IgM and IgG,
respectively, as well as slightly increased corresponding coeffi-
cients of variation of 2.66% and 2.63%, respectively. These data
demonstrate that the assay maintains strong repeatability even
when compounded with normal human population serum vari-
ability. Taken together, these results indicate that the background
variability for iPCR detection of host-generated antibodies within
and across a healthy human population is well within acceptable
levels for the technique.
Previous studies using recombinant antigens have indicated
that no single antigen tested to date has the capability to diagnose
Lyme disease across its multiple stages and disease manifestations
(7). A panel of eight antigens was generated for use in the iPCR
assay. These proteins were selected based on previous studies that
identified B. burgdorferi immunoreactive antigens (13–27). We
first examined the level of variability of the background amplifi-
cation of each antigen across serum samples collected from
healthy individuals for both the IgM and IgG isotypes. Each anti-
gen resulted in a unique background amplification mean and
standard deviation value for each antigen-isotype combination.
This indicated that each antigen-isotype combination performed
uniquely using the current iPCR protocol. These data provided
the necessary parameters, including the mean background Cq
value and the standard deviation of that mean for determining an
Halpern et al.
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TABLE 2 iPCR using DOC/IgG demonstrates results equivalent to those of 2-tier testing for a panel of Lyme disease patient serum samples
Sample group
Sample
IDa DOC IgGb
Interpretation forc: Tier 2 bands detected for:
iPCR 2-Tier Tier 1 ELISA IgM IgG
Lyme disease stage 2
Early Lyme-EMd B1 2.24e Pos Pos Pos 41, 39, 23 58, 41, 39, 23, 18
B2 2.20 Pos Pos Pos 23 66, 45, 41, 39, 23, 18
B3 2.07 Pos Pos Pos 41, 39, 23 41, 23
B4 2.05 Pos Pos Pos 41 58, 45, 41, 39, 23, 18
B5 1.59 Pos Pos Pos 41, 23 41, 23
B6 1.45 Pos Pos Pos 41, 39, 23 66, 45, 41, 39, 23, 18
B7 1.08 Pos Pos Pos 41, 39, 23 41, 23
B8 0.80 Pos Pos Pos 41, 23 41
B9 0.52 Pos Neg Pos 23 66, 41, 23
B10 0.08 Pos Neg Equ
B11 (0.08) Neg Neg Pos 23 66, 41, 23
B12 (0.27) Neg Neg Neg 66
B13 (0.58) Neg Neg Pos 23
B14 (0.91) Neg Neg Pos 23 41, 23
B15 (1.00) Neg Neg Neg 67
B16 (1.01) Neg Neg Neg 39, 23 23
B17 (1.22) Neg Neg Neg 23
B18 (1.48) Neg Neg Equ 23 41
B19 (1.50) Neg Neg Neg 23
B20 1.14 Pos Neg Pos 41 41, 23, 18
Lyme disease stage 2
Neuroborreliosis B21 2.64 Pos Pos Pos 41, 23 45, 41, 23
B22 2.01 Pos Pos Pos 41, 39, 23 41, 39, 23
B23 0.00 Pos Pos Pos 41, 39, 23 41, 23
B24 (0.26) Neg Neg Neg 41, 23 41, 23
Lyme carditis B25 2.83 Pos Pos Pos 41, 39, 23 66, 45, 41, 23, 18
B26 1.37 Pos Pos Pos 41, 39, 23 66, 45, 41, 23, 18
Lyme disease stage 3
Lyme arthritis B27 3.44 Pos Pos Pos 23 93, 66, 58, 45, 41, 39, 30, 28, 23, 18
B28 2.96 Pos Pos Pos 41 93, 66, 58, 41, 39, 30, 28, 23, 18
B29 2.67 Pos Pos Pos 41, 23 93, 66, 58, 45, 41, 39, 30, 28, 23, 18
B30 2.62 Pos Pos Pos 66, 58, 45, 41, 39, 28, 23, 18
B31 2.09 Pos Pos Pos 23 58, 41, 39, 23, 18
B32 1.84 Pos Pos Pos 93, 66, 58, 41, 39, 30, 23, 18
Non-Lyme
Fibromyalgia B33 (0.28) Neg Neg Neg 23
B34 (0.81) Neg Neg Neg 39 58, 41
B35 (1.70) Neg Neg Neg 41
B36 (1.89) Neg Neg Neg 41
B37 (1.93) Neg Neg Neg
B38 (2.30) Neg Neg Neg
Rheumatoid arthritis B39 (0.90) Neg Neg Pos 41
B40 (1.17) Neg Neg Neg 41
B41 (1.56) Neg Neg Neg
B42 (1.73) Neg Pos Pos 41, 23
B43 (1.77) Neg Neg Neg
B44 (2.05) Neg Neg Neg
Multiple sclerosis B45 (0.55) Neg Neg Neg 39, 23 41
B46 (0.78) Neg Neg Pos 41, 23
B47 (1.09) Neg Neg Neg
B48 (1.11) Neg Neg Neg 39
B49 (1.75) Neg Neg Neg
B50 (2.05) Neg Neg Neg 66
(Continued on following page)
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individual call threshold for each antigen-isotype combination. The
call thresholds were established as the mean background Cq value
minus a multiple of the standard deviation. The multiplier of stan-
darddeviationwasunique for each antigen-isotype combination and
established based on the minimum multiplier that resulted in no
false-positive calls for the CDC research panel I, which served as the
training set for optimizing our assay. The Cq was calculated as the
established threshold call Cq minus the Cq value of the sample. A
sample with aCq value of0 was deemed positive by iPCR. Using
the panel of eight antigens, this approach duplicated 2-tier testing
results with a single early Lymepatient sample (culture positive) test-
ing positive by iPCR thatwas negative by 2-tier testing. Samples from
individuals in the later stages of disease (neurologic and arthritis)
tended to test positive for multiple antigens.
In addition to detecting the presence of host antibodies as lab-
oratory support of an exposure to B. burgdorferi, it would be de-
TABLE 2 (Continued)
Sample group
Sample
IDa DOC IgGb
Interpretation forc: Tier 2 bands detected for:
iPCR 2-Tier Tier 1 ELISA IgM IgG
Mononucleosis B51 (0.09) Neg Neg Neg 39
B52 (0.28) Neg Neg Pos 41, 39
B53 (0.58) Neg Neg Pos
B54 (0.77) Neg Neg Equ 41
B55 (0.78) Neg Neg Neg
B56 (1.25) Neg Neg Neg 41, 23 66, 58, 41
Syphilis B57 (0.56) Neg Neg Pos
B58 (0.75) Neg Neg Pos 41
B59 (0.96) Neg Neg Pos 41
B60 (1.01) Neg Pos Pos 39, 23
B61 (1.38) Neg Neg Pos 41
B62 (1.47) Neg Neg Neg
Severe periodontitis B63 (0.22) Neg Neg Neg
B64 (0.29) Neg Neg Neg
B65 (0.56) Neg Neg Neg
B66 (0.90) Neg Neg Neg 45, 41
B67 (1.03) Neg Neg Neg 66
B68 (3.04) Neg Neg Neg
Healthy controls
From areas of endemicity B69 0.23 Pos Neg Neg 23
B70 (0.04) Neg Neg Pos 41 66
B71 (0.53) Neg Neg Pos 41, 23
B72 (0.87) Neg Neg Neg 23 41
B73 (0.87) Neg Neg Equ 23
B74 (1.11) Neg Neg Neg 45, 41
B75 (1.16) Neg Neg Neg
B76 (1.37) Neg Neg Neg
B77 (1.42) Neg Neg Neg
B78 (1.49) Neg Neg Neg 66, 41
B79 (1.95) Neg Neg Neg 23
B80 (2.47) Neg Neg Pos 23 58, 41, 39, 18
From areas of nonendemicity B81 (0.53) Neg Neg Neg 41
B82 (0.60) Neg Neg Neg 41, 23 41
B83 (0.78) Neg Neg Equ
B84 (0.80) Neg Neg Pos
B85 (0.86) Neg Neg Neg
B86 (0.90) Neg Neg Neg 58, 45
B87 (1.09) Neg Neg Neg 66, 58, 45, 41
B88 (1.15) Neg Neg Neg 41
B89 (1.17) Neg Neg Neg 41
B90 (1.77) Neg Neg Neg 23
B91 (2.06) Neg Neg Neg 23
B92 (2.09) Neg Neg Neg
a ID, identification.
b Values shown represent a Cq in reference to the antigen/isotype background threshold Cq value determined using an antigen-specific multiplier of the standard deviation (SD)
above the mean value for a set of healthy individuals for each antigen/isotype combination, as described in Materials and Methods. The values in parentheses represent negative
iPCR Cq values.
c Two-tier results were established by standard ELISA and IgG/IgM immunoblot (IB) protocols. Pos, positive; Neg, negative; Equ, equivocal.
d EM, erythema migrans.
e Bold type indicates positive assay results/interpretations.
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sirable to link an antibody profile with the clinical stage (i.e., early
localized, early disseminatedwith neurological or cardiac involve-
ment, or Lyme arthritis) of illness to better understand disease
progression. The results from the human serum panel iPCR test-
ing classified both late Lyme arthritis samples as strongly positive
for IgG using the RevA and Crasp2 proteins, with all other cate-
gories of samples testing negative for the same two proteins. These
results suggest that these two proteins may specifically illicit an
immune response in a Lyme arthritis patient as opposed to those
in other stages of Lyme disease. However, analysis of a greater
number of clinically defined samples is required to further sup-
port these observations.
Limited studies have shown promising results using antigens
composed of multiple antigenic portions of various seroreactive
proteins to detect B. burgdorferi antibodies in human patient sera
(24, 37, 38). The demonstration of iPCR equivalency to 2-tier
testing using a panel of antigens led us to surmise that a more
simplified version of the protocol using a single hybrid antigen
was likely to be successful. Three antigens known to be seroreac-
tive at different stages of the disease (DbpA, OspC, andVlsE) were
synthetically joined by combining the seroreactive peptide por-
tions of OspC (39) and VlsE (40) with the full-length DbpA pro-
tein into a single recombinant hybrid antigen we termed DOC.
The mean background was established for 16 healthy individuals
using DOC and showed little variation (standard deviation, 0.57
and 0.51 for anti-B. burgdorferi IgM and IgG antibodies, respec-
tively), similar to the results for the full-length antigens tested. The
DOC antigen was then used to test CDC research panel I for an-
ti-B. burgdorferi IgM and IgG antibodies to establish a positive call
threshold. Using the positive call threshold, the DOC iPCR IgG
assay demonstrated results equivalent to those for 2-tier testing,
with all 2-tier positives identified as positive by iPCR. The quan-
tification of the Cq for Lyme disease patients showed a trend of
increasing average values from early Lyme acute (1.61) to con-
valescent early Lyme (0.67) to late-stage Lyme (2.39), suggesting a
correlation in the amount of detectable B. burgdorferi antibody
with disease stage. Interestingly, DOC iPCR IgM was negative for
all samples tested, including Lyme disease patient samples. The
full-length DbpA antigen alone resulted in a low-positive IgM
iPCR value (0.69) for only a single Lyme disease patient sample.
iPCR testing using the full-length OspC antigen resulted in a
number of IgM iPCR-positive samples, suggesting that the anti-
bodies detected in these samples may have resulted from OspC
epitopes other than the PEPC10 sequence. It is also possible that in
the context of the DOC hybrid antigen, the PEPC10 sequence
lacks the conformational epitope(s) required for IgM recognition.
It is well documented that the VlsE antigen primarily generates
IgG rather than IgM antibodies early in infection (41). Therefore,
it may not be surprising that the DOC antigen detects IgG anti-
bodies only. These results indicate that testing only the IgG frac-
tion using theDOChybrid antigenwas necessary to achieve a level
of sensitivity equivalent to that of 2-tier testing, which required
IgM for positive detection in some samples. Given the small sam-
ple size, these findings do not rule out the possibility that IgM
antibodies might be detected with the DOC iPCR assay in some
Lyme disease patient serum samples. Moreover, the additional
optimization of the hybrid antigen to include the specific detec-
tion of IgM antibodies may contribute to further improved sensi-
tivity for detecting disease in patients with early Lyme disease.
Nonetheless, IgM detection has been problematic and controver-
sial due to its contribution to false-positive results and the require-
ment that IgM testing be used only within the first 4 weeks of
infection (7), suggesting that an assay that does not use IgM may
represent an improvement over the currentmethods of testing for
Lyme disease. In addition, our data suggest that there exists the
potential to determine the stage of disease based on the Cq value
of the DOC iPCR assay, which represents another possible im-
provement over current Lyme disease diagnostics.
iPCR testing of the anti-B. burgdorferi IgG antibody fraction
using the DOC hybrid antigen was successful at duplicating the
2-tier testing results for a small panel of samples. We then pro-
ceeded to test a larger blinded panel of 92 samples composed of
serum samples fromLyme patients (early, early disseminatedwith
cardiac or neurological involvement, and Lyme arthritis), those
with look-alike diseases (fibromyalgia, mononucleosis, multiple
sclerosis, rheumatoid arthritis, severe periodontitis, and syphilis),
and healthy (from areas of endemicity and nonendemicity) indi-
viduals (CDC research panel II). iPCR demonstrated 69% sensi-
tivity and 98% specificity compared to 59%and 97%, respectively,
for 2-tier testing. A single neurologic Lyme patient tested negative
by both iPCR and 2-tier testing. This result ismost likely due to the
fact that the serum sample was taken 7 days post-erythema mi-
grans (EM), which was likely too early in the infection process to
produce an adequate immune response.
Currently, the DOC hybrid antigen is composed of B. burgdor-
feriB31 sequences. Amino acid sequences can vary between strains
and species of Lyme disease borreliae by as much as 24% for VlsE
C6 (11), 10% for OspC PEPC10C (12), and 44% for DbpA (42).
This may be limiting if an individual is infected with other strains
or species. It is likely that the incorporation of additional protein/
peptide sequences from other species, such as Borrelia afzelii or
FIG 7 DOC hybrid antigen IgG iPCR demonstrated sensitive and specific
detection of Lyme disease for a blinded serum panel. CDC research panel II
was tested in a blinded fashion using DOC iPCR for IgG reactivity. Each dot
represents a single individual replicate, and the black horizontal lines represent
the mean Cq values for all individuals within each category. The filled circles
represent samples that were positive with 2-tier testing, and the open circles
signify a 2-tier-negative status. A positive threshold valuewas established using
amultiplier of the standard deviation (SD) above themean value, with theCq
threshold (gray horizontal line) representing a value of zero. The sensitivity
and specificity values for iPCR, each tier, and combined 2-tier testing are listed.
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Borrelia garinii, or other strains might further increase the sensi-
tivity of the assay, especially when samples from patients with
Lyme disease from Europe and other diverse locations are ana-
lyzed.
The recommended protocol for Lyme disease diagnosis re-
quires a first-tier ELISA, followed by a second-tier IgM and/or IgG
immunoblot (7). Here, we demonstrated that the simplified sin-
gle-tier DOC iPCR assay was sufficient to objectively identify all
2-tier-positive samples across two panels of well-characterized
samples from Lyme disease patients. The objective positive/nega-
tive call threshold of this sensitive and specific method represents
an important improvement over the currently accepted method.
Moreover, it is likely that future automation of this protocol will
provide additional advantages to the iPCRmethod. Emerging im-
munoassay technologies, such as the Erenna system fromSingulex
and the single-molecule array by Quanterix, provide intriguing
options for higher sensitivity and precision. Currently, these sys-
tems are considered research and development instruments for
biomarker discovery and validation. Although these platforms
present new possibilities for assay development and have the po-
tential to provide increased sensitivity, they have yet to be ac-
cepted for routine clinical diagnostics. The current iPCR protocol
uses real-time quantitative PCR (qPCR) as its method of signal
amplification and detection. Real-time qPCR has garnered accep-
tance for routine use in clinical laboratories as a detectionmethod
for a number of assays. Therefore, the use of a qPCR detection
system, which is a standard piece of equipment in many clinical
laboratories, provides a more direct route for clinical acceptance
of an iPCR-based Lyme disease diagnostic assay.
In summary, DOC iPCR shows potential as a novel diagnostic
tool for identifying host-generated antibodies against B. burgdor-
feri. It will be of interest to determine whether this test is useful for
monitoring antibody titer changes over time in samples from pa-
tients after antibiotic therapy for Lyme disease and for exploring
specialty testing using this approach to determine the stage and
the type of disease manifestations.
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